SEATTLE, Sept. 17 WA-Dendreon-UBS
SEATTLE, Sept. 17 /PRNewswire-FirstCall/ -- Dendreon Corporation
(Nasdaq: DNDN) today announced that Mitchell H. Gold, M.D., president and
chief executive officer of Dendreon, will present a company update at the UBS
Global Life Sciences Conference in New York City, on Monday, September 22,
2008 at 1:30 p.m. ET.
A live audio webcast of the presentation will be accessible through the
Investor Relations section of the Dendreon website, http://www.dendreon.com.
If you are unable to listen to the live webcast, it will be archived on the
site following the presentation. To access the replay, go to the Investor
Relations section of the website.
Dendreon Corporation is a biotechnology company whose mission is to target
cancer and transform lives through the discovery, development and
commercialization of novel therapeutics. The Company applies its expertise in
antigen identification, engineering and cell processing to produce active
cellular immunotherapy product candidates designed to stimulate an immune
response. Dendreon is also developing an orally-available small molecule
called Trp-p8 that could be applicable to multiple types of cancer as well as
benign prostatic hyperplasia. The Company has its headquarters in Seattle,
Washington and is traded on the Nasdaq Global Market under the symbol DNDN.
For more information about the Company and its programs, visit
http://www.dendreon.com.
SOURCE Dendreon Corporation
